Fenebrutinib

Overview

Fenebrutinib (GDC-0853) is a potent, selective, orally available, and noncovalent bruton's tyrosine kinase ( Btk ) inhibitor with K i s of 0.91 nM, 1.6, 1.3, 12.6, and 3.4 nM for WT Btk , and the C481S, C481R, T474I, T474M mutants. Fenebrutinib has the potential for rheumatoid arthritis and systemic lupus erythematosus research.

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Btk

Product Information

• Catalog No.: HY-19834
• CAS No.: 1434048-34-6
• Molecular Formula: C37H44N8O4
• Molecular Weight: 664.80
• Purity: 99.89%
• Storage: 4°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
• Solubility: ≥ 2 mg/mL (3.01 mM); Clear solution
• Availability: In-stock

Source

Original product source